Related Experiment Video
Updated: Sep 17, 2025
07:06
Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
Published on: December 8, 2014
27.3K
Fecal Microbiota Transplantation (FMT) in Clostridium difficile Infection: A Paradigm Shift in Gastrointestinal
Muhammad Hamza Saeed1, Sundas Qamar2, Ayesha Ishtiaq3
1Internal Medicine, Russells Hall Hospital, Dudley, GBR.
Cureus
|June 30, 2025
Summary
Fecal microbiota transplantation (FMT) shows promise for recurrent Clostridium difficile infection (CDI) by restoring gut microbiota diversity. While FMT improved patient quality of life and reduced antibiotic dependence, recurrence rates remain a concern requiring further research.
Area of Science:
- Gastroenterology
- Microbiology
- Clinical Medicine
Background:
- Clostridium difficile infection (CDI) presents significant clinical challenges, particularly in recurrent cases and those with antibiotic resistance.
- Fecal microbiota transplantation (FMT) is an emerging therapeutic strategy aimed at restoring gut microbial balance and reducing CDI recurrence.
Purpose of the Study:
- To evaluate the clinical effectiveness and safety of FMT in adult patients with recurrent or refractory CDI.
- To assess the impact of FMT on gut microbiome diversity and CDI recurrence rates.
- To compare FMT efficacy against standard antibiotic treatments for infection persistence and quality of life.
Main Methods:
- A study involving 250 patients diagnosed with CDI, comparing FMT administration via colonoscopy, nasogastric tube, enema, and oral capsules against standard antibiotic treatments.
- Assessment of FMT success rates, CDI recurrence, and changes in gut microbiome diversity using the Shannon Diversity Index.
- Monitoring of secondary outcomes including quality of life, antibiotic dependence, hospitalization rates, and inflammatory markers (WBC, CRP).
Main Results:
- FMT demonstrated a success rate of 35.2%, with 52.0% experiencing recurrence. Significant increase in gut microbiome diversity (Shannon Index from 3.96 to 5.88) and pathogen clearance (52.8% PCR toxin negative conversion) were observed.
- Secondary outcomes showed improvements in quality of life (36%), reduced antibiotic dependence (35.2%), and decreased hospitalizations (28.8%).
- Logistic regression identified age, CDI severity, and prior antibiotic exposure as predictors of FMT efficacy (p < 0.05).
Conclusions:
- FMT is a promising alternative for recurrent CDI, effectively modulating the gut microbiota and reducing infection severity.
- Further research is needed to optimize FMT protocols for long-term effectiveness and minimize recurrence risks.
- FMT offers a potential strategy to improve patient outcomes in challenging CDI cases.
Related Concept Videos
01:50What is Monogastric Digestion?
72.6K
The human body contains a monogastric digestive system. In a monogastric digestive system, the stomach only contains one chamber in which it digests food. Several other animal species also have monogastric digestive systems, including pigs, horses, dogs, and birds. This chapter, however, focuses on the human digestive system.
72.6K
01:17Drugs for Treatment of Diarrhea-Predominant IBS
312
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
312